Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Gets Clinical

Premium

Nanogen has a new CEO, and he has no doubts about why he’s there. “My leadership comes in to help transition the company into clinical diagnostics,” says Randy White. He says he’s the right person to lead the company there because “that’s where I came from.”

White’s experience includes almost two decades with National Health Laboratories, seven years as an independent consultant, and a couple of years at American Medical Laboratories, where he was most recently executive vice president of technical operations.

Now, White will lead Nanogen from pure research into applied genomics. “We’re not abandoning our research base,” he says. “That’s what took us here. We’re going to be a bifocal company.”

But as Nanogen continues with research and technology development (with existing and future partners, White says), the company will also push into developing genomics-based clinical tools. And unlike other companies that consider this a far-off concept, the new CEO doesn’t plan to wait around. “[Nanogen] is, in the very near term, capable of providing clinical diagnostic tests,” he says.

The groups that will make the most of this technology are medium-sized laboratories and hospital labs. “This will allow very complex genomic assays to be performed for less sophisticated labs. And it will allow very sophisticated labs to commercialize tests that don’t even exist today,” White says.

The other incentive, of course, is money. “We think our technology will ultimately result in a lowering of the cost to perform the testing by as much as half,” he says.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.